Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
October 27 2021 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, will release financial results for
the quarter ended September 30, 2021 after the market close on
Wednesday, November 10, 2021. Ron Rocca, Exagen’s President and
Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and
Mark Hazeltine, Chief Operating Officer, will host a conference
call to review the Company’s results at 4:30 PM ET (1:30 PM PT).
Interested parties may access the conference call by dialing
(844) 826-3033 (U.S.) or (412) 317-5185 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
https://investors.exagen.com/
A replay of the conference call will be available until
Wednesday, November 17, 2021 at 11:59 PM ET (8:59 PM PT).
Interested parties may access the replay of the conference call by
dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international)
using passcode 10161457. Additionally, a recording of the webcast
will be available using the link on the Exagen investor relations
website approximately 30 minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Oct 2023 to Oct 2024